Historique
Article de Périodique
Clinical management of psychostimulant withdrawal: review of the evidence (2023)
Auteur(s) :
LI, M. J. ;
SHOPTAW, S. J.
Année
2023
Page(s) :
750-762
Sous-type de document :
Revue de la littérature / Literature review
Langue(s) :
Anglais
Refs biblio. :
99
Domaine :
Drogues illicites / Illicit drugs
Thésaurus mots-clés
AMPHETAMINE
;
COCAINE
;
METHAMPHETAMINE
;
TRAITEMENT
;
SEVRAGE
;
PHARMACOTHERAPIE
;
EFFICACITE
;
DEPENDANCE
;
PRISE EN CHARGE
;
SYNDROME DE SEVRAGE
;
SYMPTOME
Résumé :
It is estimated that a majority of people who use psychostimulants, particularly methamphetamine (MA) and cocaine, experience withdrawal upon abstinence from sustained use. This review of clinical research reports the evidence regarding biomedical and behavioral treatments for psychostimulant withdrawal symptoms. It provides a framework for clinicians and scientists to increase impact on attenuating MA and cocaine withdrawal during initial and sustained abstinence. Articles reviewed included reports of controlled clinical trials (randomized or non-randomized) reporting at least one withdrawal symptom among the outcomes or specifically studying patients in withdrawal. Potential efficacy for MA withdrawal is noted for a few medications (mirtazapine, naltrexone, bupropion) and repetitive transcranial magnetic stimulation during acute (first week), early protracted (weeks 2-4) and late protracted (> 4 weeks) withdrawal phases. Topiramate shows mixed evidence of efficacy for cocaine withdrawal. In general, there is inconsistent signal for biomedical and behavioral treatments on MA and cocaine withdrawal.
Affiliation :
Department of Family Medicine, University of California, Los Angeles, CA, USA
Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA
Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA
Cote :
Abonnement